Sold as Ultravist 370, Ultravist 300, Ultravist 240, Ultravist 150, Ultravist 300 In Plastic Container and 1 more. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 2 applications for Iopromide (sold as Ultravist 370, Ultravist 300, Ultravist 240 and others), first approved May 10, 1995, with 5 new uses approved and 0 published complete response letters.
| Contrast Volume as a Predictor of Kidney Injury Following Contrast-Enhanced CTContrast-Associated Acute Kidney Injury, Acute Kidney Injury · Assiut University | — | Not yet recruiting | Sep 10, 2026 |
| Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance ImagingBreast Cancer · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not applicable | Not yet recruiting | Jun 26, 2024 |
| Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery LesionsDe Novo Stenosis, Coronary Artery Disease · Xijing Hospital | Not applicable | Active, not recruiting | Sep 24, 2020 |
| May 10, 1995 | Ultravist 370, Ultravist 300NDA 20220 · New molecular entity | Bayer Hlthcare | 30 | Marketed |
| Sep 20, 2002 | UltravistNDA 21425 · New dosage form | Bayer Hlthcare | 16 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bayer Hlthcare